Table 1.Emerging Therapeutics for Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathy
Table Common Chemotherapeutics and Incidence of Reported Neuropathy
Table 3.7MM Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Table 4.Incident Population of CIPN in the United States, by Cancer Type
Table 5.Gender Specific Incidence of CIPN among cancer cases
Table 6.US Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 7.US Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 8.UK Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 9.UK Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 10.France Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 11.France Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 12.Germany Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 13.Germany Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 14.Spain Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 15.Spain Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 16.Italy Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 17.Italy Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 18.Age-Specific incidence of CIPN in Japan (2019)
Table 19.Japan Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 20.Japan Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence (2017-2030)
Table 21.Clinical Practice Guideline: Treatment of Chemotherapy-Induced Peripheral Neuropathy
Table 22.Olesoxime (TRO19622): MedImmune /Abbott Laboratories Inc.
Table 23.Calmangafodipir: Egetis Therapeutics /Solasia Pharma K.K.
Table 24.Pregabalin: Pfizer's
Table 25.Tetrodotoxin (TTX): Wex Pharmaceuticals
Table 26.Thrombomodulin alfa: Veloxis Pharmaceuticals
Table 27.Sodium selenite pentahydrate: Boryung Pharmaceutical Co., Ltd
Table 28.Memantine: Mendel AI
Table 29.Nicotinamide Riboside: ChromaDex, Inc.
Table 30.Total Market Size of Chemotherapy-Induced Peripheral Neuropathy in the 7MM
Table 31.Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in the 7MM
Table 32.US Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy
Table 33.UK Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy
Table 34.France Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy
Table 35.Germany Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy
Table 36.Spain Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy
Table 37.Italy Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy
Table 38.Japan Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030), By Therapy

Figure 1.7MM Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2020
Figure 2.7MM Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2030
Figure 3.7MM Market Share, By Epidemiology, Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2020
Figure 4.7MM Market Share, By Epidemiology, Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2030
Figure 5.Competition Landscape, 2020
Figure 6.Important components for an ideal CIPN assessment tool.
Figure 7.Impact of CIPN on Cancer Patients
Figure 8.Distribution of central nervous system cancer
Figure 9.Incidence of Different Types of Peripheral Neuropathy in USA
Figure 10.US Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 11.EU5 Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 12.UK Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 13.France Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 14.Germany Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 15.Spain Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 16.Italy Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 17.Japan Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy (2017-2030)
Figure 18.US Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)
Figure 19.UK Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)
Figure 20.France Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)
Figure 21.Germany Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)
Figure 22.Spain Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)
Figure 23.Italy Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)
Figure 24.Japan Chemotherapy-Induced Peripheral Neuropathy Market Size, US$ Mn (2017-2030)